AngloGold Ashanti Stock And Other Balance Sheet Picks for Defensive Investors

China’s latest inflation data points to softer domestic demand and weaker producer pricing power. That often pushes investors toward companies with strong balance sheets, resilient cash generation and high return on equity. These businesses can sometimes hold their ground when pricing power is under pressure. This article highlights 3 stocks from our Solid Balance Sheet and Fundamentals screener that fit that profile and may deserve a closer look now.

The stocks covered below are just a sample, with the full screen surfacing 45 more companies that also combine high return on equity, solid past performance and strong balance sheets that are not covered here. If you want to identify your own high conviction ideas quickly, head straight into the Solid Balance Sheet and Fundamentals screener to filter and analyze the full list on your terms.

AngloGold Ashanti (AU)

AngloGold Ashanti is a global gold producer that owns and operates mines across Africa, Australia and the Americas, with its flagship Geita mine in Tanzania. The business is heavily focused on precious metals, generating about $11.8b from gold and other metals, so your view on gold prices really matters here. With a market cap of around $49.1b, it sits among the larger listed gold miners worldwide.

Investors looking at AngloGold Ashanti today see a combination of strong recent earnings momentum, high return on equity and a clear plan to return cash through dividends and a $2b share buyback program. At the same time, the company is tightly linked to gold prices and faces rising cost pressures, regulatory hurdles on new projects and higher government take in some regions. These factors could squeeze future margins. The key consideration is whether its production pipeline, cost discipline and capital returns are enough to offset those risks over the coming years and justify current analyst optimism.

AngloGold Ashanti’s earnings momentum and cash returns story can look compelling, yet the real puzzle is how that lines up with gold exposure, cost pressures and future margins. Walk through the 4 key rewards and 1 important warning sign

Build your own resilient cash return shortlist

AngloGold Ashanti and the other stocks in this article all surfaced from the same Simply Wall St screen, but the real value is in shaping your own filters. Use our flexible Screener to mix metrics like valuation, future outlook, balance sheet strength and dividends, or start with any of our curated Investing Ideas.

Sandisk (SNDK)

Sandisk is a NAND flash storage specialist that supplies solid state drives and embedded flash for data centers, PCs, phones, cars and connected devices around the world. The business generates about $20.2b in revenue from developing, manufacturing, marketing and selling these storage devices and solutions. With a market cap of roughly $180.6b, Sandisk sits among the larger global storage and semiconductor companies.

Sandisk is attracting attention because AI driven data center demand, long term supply contracts and record Q4 2026 results are aligning with very strong profitability metrics, including a 72.7% return on equity and recently established high quality earnings. At the same time, investors need to weigh margin and pricing risk if NAND supply increases, the heavy investment in next generation BiCS technology, and a relatively new leadership team in a volatile stock. For investors looking for solid balance sheets and strong cash generation, a key consideration is whether today’s AI memory boom and multiyear deals can support earnings through the next memory cycle and justify current optimism around the business.

Sandisk’s AI storage story is accelerating, yet few investors have connected the dots between those long term contracts, the record Q4 2026 results and what sits inside the analyst forecasts for Sandisk

Hinge Health (HNGE)

Hinge Health delivers technology driven musculoskeletal care for self insured employers, using AI powered motion tracking, digital programs and a nerve stimulation wearable to manage acute injuries, chronic pain and rehabilitation. The company generates about $720 million in revenue from healthcare software and has a market cap of roughly $7.2b.

Hinge Health is attracting attention because it combines fast growing, profitable digital care, a solid balance sheet profile and high forecast returns on equity with AI driven efficiency gains that showed up clearly in Q2 2026, when revenue reached $212.82 million and operating margin was 29%. The Cylinder Health deal pushes the model into gastrointestinal care and complements existing migraine and MSK programs. This could lift revenue per client if execution is disciplined. Investors do need to weigh a rich P/E multiple and reliance on employer and health plan spending, especially if benefit budgets tighten or regulators take a harder look at AI in clinical care. The key question is whether Hinge Health’s earnings, cash generation and expanding care platform can justify that premium over time.

Hinge Health’s profitable growth and 29% operating margin in Q2 2026 suggest that the story is still in its early stages. See how the market is pricing that expansion inside the analyst forecasts for Hinge Health

Seeking Fresh Alternatives Before Others Do

Some stocks only show clear breakout momentum for a short window. Spot fresh ideas flying under the radar for now, before the crowd catches up. Consider researching them promptly.

• Seek income opportunities by scanning a curated pool of dependable payers inside the 8 dividend fortresses before yields change or valuations move away.
• Explore infrastructure companies linked to AI, automation and data growth through the hand picked universe in the 37 power grid technology and infrastructure stocks while they may still be less widely followed.
• Look for early stage potential in high quality miners by sorting the carefully filtered 29 elite gold producer stocks before the next commodity headline attracts wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com